Cardiovascular and Renal Benefits of Canagliflozin

Introduction to Canagliflozin Therapy

The American Heart Association recommends canagliflozin as an add-on therapy for patients with type 2 diabetes, reducing major adverse cardiovascular events (MACE) by 14% compared to placebo 1
The European Society of Cardiology suggests that canagliflozin provides cardiovascular benefits in patients with type 2 diabetes, with a significant reduction in MACE 1

The American Diabetes Association notes that when adding canagliflozin to a regimen containing sulfonylureas, monitor for hypoglycemia as the combination may increase this risk 3
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines state that canagliflozin can be safely used with sitagliptin without dose adjustments 4
The American College of Cardiology recommends careful monitoring when initiating canagliflozin in patients on insulin, as insulin doses may need adjustment to prevent hypoglycemia 2

The National Kidney Foundation suggests assessing the patient's estimated glomerular filtration rate (eGFR) before initiating canagliflozin 2
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend limiting the maximum dose to 100 mg daily if eGFR is 30-44 mL/min/1.73 m² 2
The European Renal Association notes that if eGFR is <30 mL/min/1.73 m², initiation is not recommended, though it may be continued at 100 mg daily if already started and tolerated 2

The American Heart Association recommends canagliflozin for patients with established cardiovascular disease to reduce cardiovascular events 5

The Infectious Diseases Society of America notes that patients on SGLT2 inhibitors should be monitored for genital mycotic infections, which occur in approximately 6% of patients 2
The American Society of Nephrology suggests assessing for volume depletion, especially in patients on multiple medications that can affect fluid status 2
The Endocrine Society recommends being vigilant for euglycemic diabetic ketoacidosis, particularly during periods of acute illness or reduced food intake 6

The American Diabetes Association recommends starting with canagliflozin 100 mg daily, regardless of renal function (assuming eGFR ≥30 mL/min/1.73 m²) 2
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest scheduling follow-up within 2-4 weeks to assess volume status, glycemic control, and potential side effects 2
The American College of Cardiology recommends considering maintaining at least low-dose insulin to prevent ketoacidosis risk 2
The Endocrine Society suggests educating the patient on sick-day management, including temporary discontinuation during acute illness or before surgical procedures 6
The National Kidney Foundation notes that renal function should be monitored regularly, as the patient is on multiple medications that can affect kidney function 2